Bizarre Patents
An electrified table cloth for preventing crawling insects from gaining access to the consumer's food or drink.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7759492 | Enantioselective synthesis of 13-oxotricyclo[8.2.1.0.] trideca-3(8),4,6-triene-5-carboxylates An enantioselective route to compounds of formula I is disclosed: The compounds of formula I are key intermediates in the synthesis of compounds useful in treatment of Alzheimer's disease. ... | 07/20/2010 |
| 7696192 | Tricyclic anilide spirolactam CGRP receptor antagonists The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, J, K, T, U, V, W, X, Y, Z, R4, R5a, R5b, R | 04/13/2010 |
| 7659300 | Monocyclic anilide spirolactam CGRP receptor antagonists The present invention is directed to compounds of Formula I: I (where A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treat... | 02/09/2010 |
| 7659264 | CGRP receptor antagonists The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and use... | 02/09/2010 |
| 7655675 | Gamma-secretase inhibitors Compounds of formula I: inhibit the processing of APP by gamma-secretase and hence find use in treatment of Alzheimer's disease. ... | 02/02/2010 |
| 7655644 | Piperidine and azetidine derivatives as GlyT1 inhibitors The present invention provides compounds of formula (I), wherein both p's are one or two, R1 is generally heteroaryl or cycloalkyl, R2 is C3-6cycloalkyl or phenyl and R3 is heteroaryl, and pharmaceutically acceptable salts... | 02/02/2010 |
| 7645790 | Hydroisoindoline tachykinin receptor antagonists The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formula... | 01/12/2010 |
| 7645756 | Nitrogenous fused heteroaromatic ring derivative The invention provides a compound or its pharmaceutically-acceptable salt of formula wherein A1 is a hydrogen, etc.; j and k are 0 or 1; is a double bond, etc.; is a doub... | 01/12/2010 |
| 7632832 | CGRP receptor antagonists Compounds of Formula I: (where variables R1, R2, R3, R7, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster... | 12/15/2009 |
| 7626056 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia The present invention provides compounds of formula I: wherein R1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R2 is a phenyl, heterocycly... | 12/01/2009 |
| 7625901 | Substituted monocyclic CGRP receptor antagonists Compounds of formula I: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, R | 12/01/2009 |
| 7595344 | Sulphones which modulate the action of gamma secretase Disclosed are sulphones which modulate the action of gamma-secretase. The compounds are useful in the treatment or prevention of Alzheimer's disease. ... | 09/29/2009 |
| 7595316 | Heteroaryloxy nitrogenous saturated heterocyclic derivative Compound of the formula: (I) [wherein each of X1, X2 and X3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically ac... | 09/29/2009 |
| 7592456 | Arylsulfonylnaphthalene derivatives as 5HTantagonists Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS. ... | 09/22/2009 |
| 7592360 | 3-fluoro-piperidines as NMDA/NR2B antagonists Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for treating conditions such as, for example, Parkinson's disease, Alzheimer's disease, migraine, epilepsy and pain. ... | 09/22/2009 |
| 7592337 | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ri... | 09/22/2009 |
| 7589116 | Biaryl substituted pyrazoles as sodium channel blockers Biaryl substituted pyrazole compounds are sodium channel blockers useful for the treatment of pain and other conditions. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutical... | 09/15/2009 |
| 7576122 | Ophthalmic compositions for treating ocular hypertension This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the us... | 08/18/2009 |
| 7576083 | Morpholinyl piperidine glycine transporter inhibitors The present invention is directed to morpholinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunctio... | 08/18/2009 |
| 7572822 | Biaryl substituted triazoles as sodium channel blockers Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, eit... | 08/11/2009 |
| 7572792 | Azetidine glycine transporter inhibitors The present invention is directed to azetidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and disease... | 08/11/2009 |
| 7569592 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 Pyrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia,... | 08/04/2009 |
| 7563816 | Ophthalmic compositions for treating ocular hypertension This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the ... | 07/21/2009 |
| 7563807 | Removal of aldehyde impurity by reactive polystyrene resini A purification method in the preparation of a substituted 8-arylquinoline, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, utilizes a polystyrene-based sulfonylhydrazine reactive resin to remove an aldehyde impurity. ... | 07/21/2009 |
| 7550481 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. ... | 06/23/2009 |
| 7550470 | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogen... | 06/23/2009 |
| 7547720 | Ophthalmic compositions for treating ocular hypertension This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use... | 06/16/2009 |
| 7547693 | Piperidine derivative Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/conge... | 06/16/2009 |
| 7544815 | Process for making hydroisoindoline tachykinin receptor antagonists The present invention is directed to a process for preparing certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful in the treatment of cer... | 06/09/2009 |
| 7534784 | CGRP receptor antagonists The present invention is directed to compounds of Formula I: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CG... | 05/19/2009 |
| 7528163 | Ophthalmic compositions for treating ocular hypertension This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use... | 05/05/2009 |
| 7521455 | Fused ring 4-oxopyrimidine derivative The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circ... | 04/21/2009 |
| 7514459 | Gamma-secretase inhibitors Compounds of formula I: are potent inhibitors of gamma-secretase and hence find use in treatment or prevention of diseases associated with deposition of β-amyloid. ... | 04/07/2009 |
| 7514253 | URA5 gene and methods for stable genetic integration in yeast A novel gene encoding P. pastoris orotate-phosphoribosyl transferase (URA5) is disclosed. Methods for producing and selecting yeast strains capable of stable genetic integration of heterologous sequences into the host genome are also provided. ... | 04/07/2009 |
| 7507836 | Benzamide modulators of metabotropic glutamate receptors The present invention is directed to compounds which are allosteric modulators of metabotropic glutamate receptors, including the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate... | 03/24/2009 |
| 7495029 | Prodrugs of (2R)-2-propyloctanoic acid for the treatment of stroke Disclosed are prodrugs of (2R)-2-propyloctanoic acid, and pharmaceutical compositions comprising them, which may be effective in modulating multiple events in the biochemical cascade of stroke. Also disclosed are methods of treating patients who have had a stroke, o... | 02/24/2009 |
| 7494983 | Ophthalmic compositions for treating ocular hypertension This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relate... | 02/24/2009 |
| 7491713 | CGRP receptor antagonists Compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, D, G, J, Q, T, W, X and Y are as defined herein) useful ... | 02/17/2009 |
| 7485640 | Imidazopyrazinones as GABA-A receptor anxiolytics The present invention discloses a compound of formula I, or a pharmaceutically acceptable salt thereof: (I) wherein —U—V— represents —CH═CH—, or —CH2—CH2—, —N═CH— or —CH═N—; X1 represents hydrogen, halog... | 02/03/2009 |
| 7482456 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors Novel substituted 8-phenylquinolines represented by Formula (I), wherein the phenyl group at the 8-position contains an aryl or heteroaryl substituent in the meta position, are PDE4 inhibitors. ... | 01/27/2009 |
